NCT02862548已完成2 期
A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Subjects With Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation
研究概览
简要总结
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF)-containing regimens at Week 24 in participants with chronic hepatitis B virus (HBV) infection and Stage 2 or greater chronic kidney disease who have received a liver transplant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures
- •Documented evidence of chronic HBV infection prior to transplantation
- •Primary or secondary (re-transplant), liver alone or liver and kidney transplant recipient from deceased or living donor
- •Liver Transplant ≥ 12 weeks prior to screening
- •Maintained on TDF alone or in combination with other approved antivirals for HBV prophylaxis or treatment
- •Have been on approved HBV oral antiviral (OAV) treatment for at least 12 weeks post-transplant prior to screening, with HBV DNA < lower limit of quantification (LLOQ) at screening
- •Screening estimated glomerular filtration rate using the chronic kidney disease epidemiology collaboration (eGFR_CKD-EPI) < 90 ml/min/1.73m^2
- •Male participants and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
- •Women considered of child bearing potential must have a negative serum pregnancy test at Screening and a negative urine test at Baseline before dosing
- •Must be willing and able to comply with all study requirements
排除标准
- •Multi-organ transplant that includes heart or lung recipient (participants who have their liver transplant as part of a liver-kidney dual transplant are eligible to enroll)
- •Participants with history of de novo or recurrent hepatocellular carcinoma (HCC) post-transplant and at screening
- •Histological evidence of unresolved transplant rejection
- •Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated cirrhosis
- •Participants meeting any of the following laboratory parameters at screening:
- •Alanine aminotransferase (ALT) > 10 × the upper limit of normal (ULN)
- •International normalized ratio (INR) > 1.5 × ULN unless the participant is stable on anticoagulant regimen affecting INR
- •Albumin < 3.0 g/dL
- •Direct bilirubin ≥ 4 × ULN
- •Platelet count < 50,000/mL
- •Co-infection with HIV or hepatitis C virus (HCV)
- •Recent (within 4 weeks of Screening) episode or infection requiring systemic antibiotics
- •Use of any prohibited medications listed within 28 days of the Baseline/Day 1 visit
- •Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (e.g., basal cell skin cancer, etc.) or hepatocellular carcinoma. Participants under evaluation for possible malignancy are not eligible
- •Significant cardiovascular, pulmonary, or neurological disease
- •Use of investigational agents within 3 months of screening, unless allowed by the Sponsor
- •Use of any prohibited medications
- •Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance
- •Known hypersensitivity to study drugs, metabolites or formulation excipients
- •Lactating females or those who may wish to become pregnant during the course of the study
- •NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
研究组 & 干预措施
TAF
Experimental
TAF 25 mg once daily for 48 weeks
干预措施: TAF (Drug)
TDF-Containing Regimens
Active Comparator
TDF alone or in combination with other approved antivirals per local practice for 48 weeks
干预措施: TDF (Drug)
TDF-Containing Regimens
Active Comparator
TDF alone or in combination with other approved antivirals per local practice for 48 weeks
干预措施: Other approved antivirals (Drug)
Optional Treatment Extension Phase
Experimental
After Week 48, participants will be eligible to receive TAF 25 mg once daily for an additional 144 weeks.
干预措施: TAF (Drug)
结局指标
主要结局
Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation
时间窗: Baseline, Week 24
Percentage of Participants With HBV DNA < 20 IU/mL at Week 24
时间窗: Week 24
次要结局
- Percent Change From Baseline in Spine BMD at Week 24(Baseline, Week 24)
- Percent Change From Baseline in Hip BMD at Week 48(Baseline, Week 48)
- Percent Change From Baseline in Spine BMD at Week 48(Baseline, Week 48)
- Change From Baseline in Serum Creatinine at Week 24(Baseline, Week 24)
- Change From Baseline in Serum Creatinine at Week 48(Baseline, Week 48)
- Change From Baseline in Serum eGFR_CKD-EPI at Week 48(Baseline, Week 48)
- Percentage of Participants With HBV DNA < 20 IU/mL at Week 48(Week 48)
- Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24(Baseline, Week 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C CirrhosisHepatitis C Virus InfectionNCT02994056Gilead Sciences32
已完成
2 期
Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal DiseaseHepatitis C Virus InfectionNCT03036839Gilead Sciences95
已完成
2 期
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal DiseaseChronic Hepatitis CNCT03036852Gilead Sciences59
招募中
2 期
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)Pulmonary Arterial HypertensionNCT05587712Merck Sharp & Dohme LLC42
已完成
2 期
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral RegimenHepatitis C Virus InfectionNCT02536313Gilead Sciences49